Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: A phase II study

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 3009-3013

  Mambrini, Andrea ^a   Guglielmi, Alfredo ^b   Pacetti, Paola ^a   Iacono, Calogero ^b   Torri, Tito ^a   Auci, Alessio ^a   Nicoli, Nicola ^c   Orlandi, Massimo ^a   Guadagni, Stefano ^d   Fiorentini, Giammaria ^e   Cantore, Maurizio ^a,f  

^a Carrara City Hospital   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c Department of Surgery   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e SAN GIUSEPPE HOSPITAL   (Italy)

^f Presidio Ospedaliero di Carrara ^*  (Italy)

Author keywords

Biliary cancer; Capecitabine; Cisplatin; Epirubicin; Intra arterial chemotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; EPIRUBICIN; HISTAMINE H3 RECEPTOR ANTAGONIST;

ADULT; AGED; ALOPECIA; ANEMIA; APHTHOUS STOMATITIS; ARTICLE; BILE DUCT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CHOLANGIOCARCINOMA; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED;

EID: 34547732537     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Davila JA and El Serag HB: Cholangiocarcinoma: the "other" liver cancer on rise. Am J Gastroenterol 97: 3199-3200, 2002.
2. Klempnauer J, Ridder GJ and Werner M: What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer 79: 26-34, 1997.
3. Nakeeb A, Pitt HA and Sohn TA: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224: 463-475, 1996.
4. Roberts JW and Daugherty SF: Primary carcinoma of the gallbladder. Surg Clin North Am 66: 743-749, 1986.
5. Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H and Katagiri S: Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 8: 154-157, 2001.
6. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y and Blumgart LH: Intrahepatic cholangiocarcinoma: resectability, recurrence pattern and outcomes. J Am Coll Surg 193: 384-391, 2001.
7. Rajagopalan V, Daines WP, Grossbard ML and Kozuch P: Gallbladder and biliary tract carcinoma: a comprehensive update - Part 1. Oncology 18: 889-896, 2004.
8. Daines WP, Rajagopalan V, Grossbard ML and Kozuch P: Gallbladder and biliary tract carcinoma: a comprehensive update - Part 2. Oncology 18: 1049-1054, 2004.
9. Olnes MJ and Erlich R: A review and update on cholangiocarcinoma. Oncology 66: 167-179, 2004.
10. Oberfield RA and Rossi RL: The role of chemotherapy in the treatment of bile duct cancer. World Surg 12: 105-108, 1988.
11. Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T and Cunningham D: Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 31: 1594-1598, 1995.
12. Northover JM and Terblanche J: A new look at the arterial supply of the bile duct in man and its surgical implication. Br J Surg 80: 912-915, 1993.
13. Miller DL, Carrasquillo JA, Lutz RJ and Chang AE: Hepatic perfusion during hepatic arterial infusion chemotherapy: evaluation with perfusion CT and perfusion scintigraphy. J Comput Assist Tomogr 13: 958-964, 1989.
14. Mäkelä JT and Kairaluoma MI: Superselective intra-arterial chemotherapy with mitomycin C for gallbladder cancer. Br J Surg 80: 912-915, 2002.
15. Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamagni D, Caudana R, Pennucci C, Sanguinetti F, Lombardo M and Nicoli N: Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 103: 1402-1407, 2005.
16. Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C and Brown TD: Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma and gallbladder cancer). Cancer 101: 578-586, 2004.
17. Park SH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB and Lee JH: Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer 106: 361-365, 2006.
18. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J and Moore MJ: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23: 2332-2338, 2005.
19. Simon R: Optimal two-stage design for phase II clinical trials in oncology. Control Clin Trials 10: 1-10, 1989.
20. Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115-125, 2004.
21. Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A and Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 15: 947-954, 1997.
22. Meier CG, Penn I and James L: Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 69: 1633-1637, 2000.
23. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T and Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7: 593-600, 1996.
24. Kim ST, Park JO, Lee J, Lee JK, Choi SH, Heo JS, Park YS, Kang WK and Park K: A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106: 1339-1346, 2006.
25. Park BK, Kim YJ, Park J, Bang S, Park SW, Chung JB, Kim SK, Choi JS, Lee WJ and Song SY: Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. J Gastroenterol Hepatol 21: 999-1003, 2006.
26. Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, Geissler M, Opitz O and Henss H: Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with bibliary tract cancer. Cancer 95: 848-852, 2006.
27. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H and Tsuyuguchi T: Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57: 647-653, 2006.
28. Yamashita YI, Taketomi A, Fukuzawa K, Yoshizumi T, Uchiyama H, Simada M, Shirabe K, Wakasugi K and Maehara Y: Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cancers: a pilot study. Anticancer Res 26: 771-776, 2006.
29. Twelves C: Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology (Williston Park) 16: 23-26, 2002.
30. Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K, Dales JP, Durand A, Milano G, Seitz JF and Lacarelle B: Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine dehydrogenase deficiency. Cancer Chemother Pharmacol 58: 272-275, 2006.
31. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, Chaussade S, Mentha G and Terris B: Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18: 299-304, 2007.